Phase II Study of TAS-106 to Treat Head and Neck Cancer

Taiho Pharma

Status and phase: Terminated; Phase 2

Conditions: Head and Neck Cancer

Treatments: Drug: TAS-106

Study type: Interventional

Funder types: Industry

Identifiers

NCT00737360

TAS106-9905

Details and patient eligibility

About

The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.

Enrollment: 27 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 ≤ years old at study entry
• Histologically confirmed head and neck carcinoma
• Received prior platinum based regimen and developed disease progression or recurrence
• Measurable disease according to RECIST guidelines

Exclusion criteria

• Radiological or clinical evidence of brain involvement or leptomeningeal disease
• ≥ grade 2 peripheral neuropathy
• History of another malignancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

27 participants in 1 patient group

1

Experimental group

Treatment:

Drug: TAS-106